Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Cost-Effectiveness of Nirsevimab and Palivizumab for Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-34 6/7 Weeks' Gestation in the United States
This study compares the cost-effectiveness of two drugs, nirsevimab and palivizumab, used to prevent respiratory syncytial virus (RSV) in preterm infants born between 29 and …